Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,766 | 335 | 2,387 |
| Samples | 859 | 161 | 682 |
| Peptides | 687 | 113 | 581 |
Function
PTPRM · Protein tyrosine phosphatase receptor type M
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain and four fibronectin type III-like repeats. This PTP has been shown to mediate cell-cell aggregation through the interaction with another molecule of this PTP on an adjacent cell. This PTP can interact with scaffolding protein RACK1/GNB2L1, which may be necessary for the downstream signaling in response to cell-cell adhesion. Alternative splicing results in multiple transcripts encoding distinct isoforms. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000580170 | P28827-2 | 951 | 670 |
| ENST00000332175 | P28827 | 842 | 626 |
| ENST00000400053 | E7EPS8* | 808 | 596 |
| ENST00000400060 | A0ACM8Q8B8* | 165 | 118 |
Gene Properties
Recurrent Mutations
All 670 amino-acid changes on canonical ENST00000580170 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPRM · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPRM – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chordoma | 3/7 43% | 0/13 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 31/612 5% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Colorectal Carcinoma | 21/143 15% | 127/3239 4% |
| Other Solid Cancers | 6/94 6% | 60/1515 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastric Carcinoma | 9/74 12% | 63/1809 3% |
| Melanoma | 9/210 4% | 64/1899 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 21/769 3% |
| Bladder Carcinoma | 5/58 9% | 19/956 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 17/752 2% |
| Neuroendocrine Tumour | 11/154 7% | 5/577 1% |
| Cervical Carcinoma | 0/35 0% | 10/422 2% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 18/810 2% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 25/1390 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 10/51 20% | 41/2550 2% |
| Head and Neck Carcinoma | 7/85 8% | 25/1574 2% |
| Ovarian Carcinoma | 6/109 6% | 12/998 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Hepatocellular Carcinoma | 5/46 11% | 25/2210 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 22/2534 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Kidney Carcinoma | 4/85 5% | 13/1862 1% |
Mutation Distribution
Where PTPRM is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPRM were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,766 mutations in PTPRM
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|